Navigation Links
Cell Therapeutics to Report Third Quarter Financial Results after Market on October 30, 2013
Date:10/22/2013

SEATTLE, Oct. 23, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its third quarter financial results on Wednesday, October 30, 2013, after the close of the U.S. financial markets.  Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m. PDT).  Access to the event can be obtained as follows:

Wednesday, October 30, 2013
1:30 p.m. PDT/4:30 p.m. EDT/10:30 p.m. CEST
1-866-225- 8754 (domestic)
+1 480-629-9819 (international)

To access the live audio webcast or the subsequent archived recording, visit CTI's website, www.celltherapeutics.com.  Webcast and telephone replays of the conference call will be available at approximately two hours after completion of the call.  Callers can access the replay by dialing 1-800-406-7325 (domestic) or +1 303-590-3030 (international).  The access code for the replay is 4647208.  The telephone replay will be available until Wednesday, November 6, 2013.

About Cell Therapeutics

Cell Therapeutics (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable.  CTI is headquartered in Seattle, WA.  For additional information and to sign up for email alerts and get RSS feeds, please visit www.CellTherapeutics.com.

Contacts:

Monique Greer
+1 206-272-4343
mgreer@ctiseattle.com

Ed Bell
+1 206.282.7100
ebell@ctiseattle.com

In Europe

CTI Life Sciences Limited, Milan Branch
Laura Villa
T: +39 02 89659706
E: lvilla@cti-lifesciences.com
CTI_EUInvestors@CTI-Lifesciences.com


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... PUNE, India , April 19, 2017 ... Type and Application, Forecast to 2022 report has covered and ... provides statistics and information on market size, shares and growth ... with major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and ...
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
Breaking Medicine Technology:
(Date:4/28/2017)... Linda, Ca (PRWEB) , ... April 28, 2017 ... ... with cardiac or hERG liability could substantially improve drug safety and minimize the ... be provided for validating ion channel inhibition using cell lines and for cardiac ...
(Date:4/28/2017)... FL (PRWEB) , ... April 28, 2017 , ... ... Florida are conducting a pilot study of ActiGraph’s CentrePoint Data Hub ... is a leading provider of clinical-grade wearable activity and sleep monitoring solutions for ...
(Date:4/28/2017)... ... , ... NuevaCare, a leading home care agency based in San Mateo, California, ... proud to announce information upgrades to its blog in the form of WordPress tags. ... such as home care (generally) as well as senior care and home care agency ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... respiratory hospital, based in Denver, Colorado, announced an agreement to create the Jane ... continuing support of the Jane and Leonard Korman Family Foundation. The collaboration leverages ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... her husband Dan Gasby the 2017 Public Leadership in Neurology Award (PLINA). The ... retired professional athlete Tedy Bruschi, Vice President Walter Mondale, actor Michael J. Fox ...
Breaking Medicine News(10 mins):